Developing a treatment for dry age-related Macular Degeneration

Oxford Bioelectronics Ltd is developing a device which it calls 'NOMAD' that seeks to use controlled application of electrical impulses to aim to stimulate nerve endings and biological processes within the eye with the intention of improving blood flow and neurogenesis (encouraging growth of new neurons) as well as reducing inflammation.  

The Company’s primary target market is the management of dry age related macular degeneration (Dry AMD or dAMD) also named as non-exudative AMD. There is currently no cure for dry related AMD making it an area of unmet medical need.

  • Product

    Life Sciences EIS
  • Sector

    Bioelectronic medicine
  • Status

  • HMRC

    Advanced Assurance